



Universiteit
Leiden
The Netherlands

Systems microscopy to unravel cellular stress response signalling in drug induced liver injury

Wink, Steven

Citation

Wink, S. (2015, December 22). *Systems microscopy to unravel cellular stress response signalling in drug induced liver injury*. Retrieved from <https://hdl.handle.net/1887/37129>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/37129>

Note: To cite this publication please use the final published version (if applicable).

Cover Page



Universiteit Leiden



The handle <http://hdl.handle.net/1887/37129> holds various files of this Leiden University dissertation

Author: Wink, Steven

Title: Systems microscopy to unravel cellular stress response signalling in drug induced liver injury

Issue Date: 2015-12-22

References

1. Lazarou, J., B.H. Pomeranz, and P.N. Corey, *Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies*. JAMA, 1998. **279**(15): p. 1200-5.
2. Einarson, T.R., *Drug-related hospital admissions*. Ann Pharmacother, 1993. **27**(7-8): p. 832-40.
3. Johnson, J.A. and J.L. Bootman, *Drug-related morbidity and mortality. A cost-of-illness model*. Arch Intern Med, 1995. **155**(18): p. 1949-56.
4. Stevens, J.L. and T.K. Baker, *The future of drug safety testing: expanding the view and narrowing the focus*. Drug Discov Today, 2009. **14**(3-4): p. 162-7.
5. Kola, I. and J. Landis, *Can the pharmaceutical industry reduce attrition rates?* Nature Reviews Drug Discovery, 2004. **3**(8): p. 711-715.
6. Kaplowitz, N., *Idiosyncratic drug hepatotoxicity*. Nat Rev Drug Discov, 2005. **4**(6): p. 489-99.
7. Regev, A., *Drug-induced liver injury and drug development: industry perspective*. Semin Liver Dis, 2014. **34**(2): p. 227-39.
8. Olson, H., et al., *Concordance of the toxicity of pharmaceuticals in humans and in animals*. Regul Toxicol Pharmacol, 2000. **32**(1): p. 56-67.
9. Donato, M.T., et al., *Cell lines: a tool for in vitro drug metabolism studies*. Curr Drug Metab, 2008. **9**(1): p. 1-11.
10. Polster, B.M., et al., *Use of potentiometric fluorophores in the measurement of mitochondrial reactive oxygen species*. Methods Enzymol, 2014. **547**: p. 225-50.
11. Grandl, M. and G. Schmitz, *Fluorescent high-content imaging allows the discrimination and quantitation of E-LDL-induced lipid droplets and Ox-LDL-generated phospholipidosis in human macrophages*. Cytometry A, 2010. **77**(3): p. 231-42.
12. Tolosa, L., et al., *High-content screening of drug-induced mitochondrial impairment in hepatic cells: effects of statins*. Arch Toxicol, 2015. **89**(10): p. 1847-60.
13. Hendriks, G., et al., *The ToxTracker assay: novel GFP reporter systems that provide mechanistic insight into the genotoxic properties of chemicals*. Toxicol Sci, 2012. **125**(1): p. 285-98.
14. Ramaiahgari, S.C., et al., *A 3D in vitro model of differentiated HepG2 cell spheroids with improved liver-like properties for repeated dose high-throughput toxicity studies*. Arch Toxicol, 2014. **88**(5): p. 1083-95.
15. Materne, E.M., et al., *The multi-organ chip--a microfluidic platform for long-term multi-tissue coculture*. J Vis Exp, 2015(98): p. e52526.
16. Godoy, P., et al., *Recent advances in 2D and 3D in vitro systems using primary hepatocytes, alternative hepatocyte sources and non-parenchymal liver cells and their use in investigating mechanisms of hepatotoxicity, cell signalling and ADME*. Arch Toxicol, 2013. **87**(8): p. 1315-530.
17. Hadi, M., et al., *Human precision-cut liver slices as an ex vivo model to study idiosyncratic drug-induced liver injury*. Chem Res Toxicol, 2013. **26**(5): p. 710-20.
18. Ruffner, H. and J. Lichtenberg, *3D cell culture systems--towards primary drug discovery platforms: an interview with Heinz Ruffner (Novartis) and Jan Lichtenberg (InSphero)*. Biotechnol J, 2012. **7**(7): p. 833-4.
19. Krueger, W., U.A. Boelsterli, and T.P. Rasmussen, *Stem Cell Strategies to Evaluate Idiosyncratic Drug-induced Liver Injury*. J Clin Transl Hepatol, 2014. **2**(3): p. 143-52.
20. Jan, Y.H., et al., *Acetaminophen reactive intermediates target hepatic thioredoxin reductase*. Chem Res Toxicol, 2014. **27**(5): p. 882-94.
21. Jaeschke, H., et al., *Mechanisms of hepatotoxicity*. Toxicol Sci, 2002. **65**(2): p. 166-76.
22. Kalinec, G.M., et al., *Acetaminophen and NAPQI are toxic to auditory cells via oxidative and endoplasmic reticulum stress-dependent pathways*. Hear Res, 2014. **313**: p. 26-37.
23. Silva, M.F., et al., *Valproic acid metabolism and its effects on mitochondrial fatty acid oxidation: a review*. J Inherit Metab Dis, 2008. **31**(2): p. 205-16.
24. Cotariu, D. and J.L. Zaidman, *Valproic acid and the liver*. Clin Chem, 1988. **34**(5): p. 890-7.
25. Kesterson, J.W., G.R. Granneman, and J.M. Machinist, *The hepatotoxicity of valproic acid and its metabolites in rats. I. Toxicologic, biochemical and histopathologic studies*. Hepatology, 1984. **4**(6): p. 1143-52.
26. Labbe, G., D. Pessayre, and B. Fromenty, *Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies*. Fundam Clin Pharmacol, 2008. **22**(4): p. 335-53.
27. Porceddu, M., et al., *Prediction of liver injury induced by chemicals in human with a multiparametric assay on isolated mouse liver mitochondria*. Toxicol Sci, 2012. **129**(2): p. 332-45.
28. Begriche, K., et al., *Drug-induced toxicity on mitochondria and lipid metabolism: mechanistic diversity and deleterious consequences for the liver*. J Hepatol, 2011. **54**(4): p. 773-94.

29. Kamei, J. and Y. Kasuya, *The effect of hydrochlorothiazide on the enhanced coughing associated with treatment with enalapril*. Eur J Pharmacol, 1992. **213**(1): p. 137-9.
30. Aluvila, S., et al., *Organization of the mitochondrial apoptotic BAK pore: oligomerization of the BAK homodimers*. J Biol Chem, 2014. **289**(5): p. 2537-51.
31. Vinken, M., et al., *Drug-induced liver injury: mechanisms, types and biomarkers*. Curr Med Chem, 2013. **20**(24): p. 3011-21.
32. Deniaud, A., et al., *Endoplasmic reticulum stress induces calcium-dependent permeability transition, mitochondrial outer membrane permeabilization and apoptosis*. Oncogene, 2008. **27**(3): p. 285-99.
33. Bertolotti, A., et al., *Dynamic interaction of BiP and ER stress transducers in the unfolded-protein response*. Nat Cell Biol, 2000. **2**(6): p. 326-32.
34. Di Sano, F., et al., *Endoplasmic reticulum stress induces apoptosis by an apoptosome-dependent but caspase 12-independent mechanism*. J Biol Chem, 2006. **281**(5): p. 2693-700.
35. Kobayashi, E., et al., *Halothane-induced liver injury is mediated by interleukin-17 in mice*. Toxicol Sci, 2009. **111**(2): p. 302-10.
36. Pirmohamed, M., D.A. Ostrov, and B.K. Park, *New genetic findings lead the way to a better understanding of fundamental mechanisms of drug hypersensitivity*. J Allergy Clin Immunol, 2015. **136**(2): p. 236-44.
37. Matsuo, K., et al., *Involvement of oxidative stress and immune- and inflammation-related factors in azathioprine-induced liver injury*. Toxicol Lett, 2014. **224**(2): p. 215-24.
38. Fredriksson, L., et al., *Diclofenac inhibits tumor necrosis factor-alpha-induced nuclear factor-kappaB activation causing synergistic hepatocyte apoptosis*. Hepatology, 2011. **53**(6): p. 2027-41.
39. Roberts, R.A., et al., *Role of the Kupffer cell in mediating hepatic toxicity and carcinogenesis*. Toxicol Sci, 2007. **96**(1): p. 2-15.
40. Klaassen, C.D. and J.Y. Cui, *Review: Mechanisms of How the Intestinal Microbiota Alters the Effects of Drugs and Bile Acids*. Drug Metab Dispos, 2015. **43**(10): p. 1505-21.
41. Krauskopf, J., et al., *Global MicroRNA Analysis in Primary Hepatocyte Cultures*. Methods Mol Biol, 2015. **1250**: p. 241-50.
42. Pennings, J.L., et al., *Gene set assembly for quantitative prediction of developmental toxicity in the embryonic stem cell test*. Toxicology, 2011. **284**(1-3): p. 63-71.
43. Hochstenbach, K., et al., *Transcriptomic fingerprints in human peripheral blood mononuclear cells indicative of genotoxic and non-genotoxic carcinogenic exposure*. Mutat Res, 2012. **746**(2): p. 124-34.
44. Kamp, H., et al., *Reproducibility and robustness of metabolome analysis in rat plasma of 28-day repeated dose toxicity studies*. Toxicol Lett, 2012. **215**(2): p. 143-9.
45. Jennings, P., et al., *An overview of transcriptional regulation in response to toxicological insult*. Arch Toxicol, 2013. **87**(1): p. 49-72.
46. Igarashi, Y., et al., *Open TG-GATEs: a large-scale toxicogenomics database*. Nucleic Acids Res, 2015. **43**(Database issue): p. D921-7.
47. Ganter, B., et al., *Toxicogenomics in drug discovery and development: mechanistic analysis of compound/class-dependent effects using the DrugMatrix database*. Pharmacogenomics, 2006. **7**(7): p. 1025-44.
48. Poser, I., et al., *BAC TransgeneOmics: a high-throughput method for exploration of protein function in mammals*. Nature Methods, 2008. **5**(5): p. 409-15.
49. Kametsky, L., et al., *Improved structure, function and compatibility for CellProfiler: modular high-throughput image analysis software*. Bioinformatics, 2011. **27**(8): p. 1179-80.
50. Fraser, W.D., *Storing and Processing Complex Data Sets with HDF5*. Aerosp Med Hum Perform, 2015. **86**(7): p. 659-61.
51. Davern, T.J., *Drug-induced liver disease*. Clin. Liver Dis., 2012. **16**(2): p. 231-45.
52. Holt, M.P. and C. Ju, *Mechanisms of drug-induced liver injury*. AAPS J., 2006. **8**(1): p. E48-54.
53. Silva, F.G., *Chemical-induced nephropathy: a review of the renal tubulointerstitial lesions in humans*. Toxicol. Pathol., 2004. **32 Suppl 2**: p. 71-84.
54. Wolf, J. and W.R. Levis, *The study of simple chemicals in animals and man: mechanisms of contact sensitivity*. J. Drugs. Dermatol., 2012. **11**(10): p. 1166-73.
55. Hayes, A. and S. Bakand, *Inhalation toxicology*. EXS, 2010. **100**: p. 461-88.
56. Mariussen, E., *Neurotoxic effects of perfluoroalkylated compounds: mechanisms of action and environmental relevance*. Arch Toxicol, 2012. **86**(9): p. 1349-67.
57. Kinter, L.B. and J.P. Valentin, *Safety pharmacology and risk assessment*. Fundam Clin Pharmacol, 2002. **16**(3): p. 175-82.
58. Hall, A.P., et al., *Liver hypertrophy: a review of adaptive (adverse and non-adverse) changes--conclusions from the 3rd International ESTP Expert Workshop*. Toxicol Pathol, 2012. **40**(7): p. 971-94.

59. Liefvendahl, E. and H.J. Arnqvist, *Mitogenic effect of the insulin analogue glargine in malignant cells in comparison with insulin and IGF-I*. *Horm Metab Res*, 2008. **40**(6): p. 369-74.
60. Andersen, M.E., et al., *The future of toxicity testing*. *J Toxicol Environ Health B Crit Rev*, 2010. **13**(2-4): p. 163-96.
61. van Vliet, E., *Current standing and future prospects for the technologies proposed to transform toxicity testing in the 21st century*. *ALTEX*, 2011. **28**(1): p. 17-44.
62. *National Research Council: Toxicity testing in the 21st century: a vision and a strategy*.
63. Ankley, G.T., et al., *Adverse outcome pathways: a conceptual framework to support ecotoxicology research and risk assessment*. *Environ Toxicol Chem*, 2010. **29**(3): p. 730-41.
64. Peters, T.S., *Do preclinical testing strategies help predict human hepatotoxic potentials?* *Toxicol Pathol*, 2005. **33**(1): p. 146-54.
65. Ramirez, T., et al., *Metabolomics in toxicology and preclinical research*. *ALTEX*, 2013. **30**(2): p. 209-25.
66. Chen, M., et al., *A decade of toxicogenomic research and its contribution to toxicological science*. *Toxicol Sci*, 2012. **130**(2): p. 217-28.
67. Zhang, M., M. Chen, and W. Tong, *Is toxicogenomics a more reliable and sensitive biomarker than conventional indicators from rats to predict drug-induced liver injury in humans?* *Chem Res Toxicol*, 2012. **25**(1): p. 122-9.
68. Ellinger-Ziegelbauer, H., et al., *Application of toxicogenomics to study mechanisms of genotoxicity and carcinogenicity*. *Toxicol Lett*, 2009. **186**(1): p. 36-44.
69. Ryan, T.P., J.L. Stevens, and C.E. Thomas, *Strategic applications of toxicogenomics in early drug discovery*. *Curr Opin Pharmacol*, 2008. **8**(5): p. 654-60.
70. Uehara, T., et al., *The Japanese toxicogenomics project: application of toxicogenomics*. *Mol Nutr Food Res*, 2010. **54**(2): p. 218-27.
71. Yamada, F., et al., *Toxicogenomics discrimination of potential hepatocarcinogenicity of non-genotoxic compounds in rat liver*. *J Appl Toxicol*, 2012.
72. Hirode, M., et al., *Gene expression profiling in rat liver treated with compounds inducing elevation of bilirubin*. *Hum Exp Toxicol*, 2009. **28**(4): p. 231-44.
73. Hirode, M., et al., *Gene expression profiling in rat liver treated with various hepatotoxic-compounds inducing coagulopathy*. *J Toxicol Sci*, 2009. **34**(3): p. 281-93.
74. Carreras Puigvert, J., et al., *Systems biology approach identifies the kinase Csnk1a1 as a regulator of the DNA damage response in embryonic stem cells*. *Sci Signal*, 2013. **6**(259): p. ra5.
75. Pines, A., et al., *Global phosphoproteome profiling reveals unanticipated networks responsive to cisplatin treatment of embryonic stem cells*. *Mol Cell Biol*, 2011. **31**(24): p. 4964-77.
76. von Stechow, L., et al., *Identification of Cisplatin-regulated metabolic pathways in pluripotent stem cells*. *PLoS One*, 2013. **8**(10): p. e76476.
77. Porter, E., et al., *Use of an avian hepatocyte assay and the avian ToxChip PCR array for testing prioritization of 16 organic flame retardants*. *Environ Toxicol Chem*, 2013.
78. Krutzik, P.O., et al., *Phospho flow cytometry methods for the analysis of kinase signalling in cell lines and primary human blood samples*. *Methods Mol Biol*, 2011. **699**: p. 179-202.
79. LeCluyse, E.L., et al., *Organotypic liver culture models: meeting current challenges in toxicity testing*. *Crit Rev Toxicol*, 2012. **42**(6): p. 501-48.
80. Gerlier, D. and N. Thomasset, *Use of MTT colorimetric assay to measure cell activation*. *J Immunol Methods*, 1986. **94**(1-2): p. 57-63.
81. Malich, G., B. Markovic, and C. Winder, *The sensitivity and specificity of the MTS tetrazolium assay for detecting the in vitro cytotoxicity of 20 chemicals using human cell lines*. *Toxicology*, 1997. **124**(3): p. 179-92.
82. Miret, S., E.M. De Groene, and W. Klaffke, *Comparison of in vitro assays of cellular toxicity in the human hepatic cell line HepG2*. *J Biomol Screen*, 2006. **11**(2): p. 184-93.
83. Fernandez-Cruz, E., et al., *Hepatocyte damage induced by lymphocytes from patients with chronic liver diseases, as detected by LDH release*. *Clin Exp Immunol*, 1978. **31**(3): p. 436-42.
84. Tolosa, L., et al., *Development of a multiparametric cell-based protocol to screen and classify the hepatotoxicity potential of drugs*. *Toxicol Sci*, 2012. **127**(1): p. 187-98.
85. Zanella, F., J.B. Lorens, and W. Link, *High content screening: seeing is believing*. *Trends Biotechnol*, 2010. **28**(5): p. 237-45.
86. Thomas, N., *High-content screening: a decade of evolution*. *J Biomol Screen*, 2010. **15**(1): p. 1-9.
87. Steinberg, P., *High-throughput screening methods in toxicity testing*. xv, 552 pages.
88. Zhang, G., et al., *Early detection of apoptosis using a fluorescent conjugate of annexin V*. *Biotechniques*, 1997. **23**(3): p. 525-31.
89. Listenberger, L.L. and D.A. Brown, *Fluorescent detection of lipid droplets and associated proteins*. *Curr Protoc Cell Biol*, 2007. **Chapter 24**: p. Unit 24 2.

90. van de Water, F.M., et al., *High content screening analysis of phospholipidosis: validation of a 96-well assay with CHO-K1 and HepG2 cells for the prediction of in vivo based phospholipidosis*. *Toxicol In Vitro*, 2011. **25**(8): p. 1870-82.
91. O'Brien, P.J., et al., *High concordance of drug-induced human hepatotoxicity with in vitro cytotoxicity measured in a novel cell-based model using high content screening*. *Arch Toxicol*, 2006. **80**(9): p. 580-604.
92. Peyker, A., O. Rocks, and P.I. Bastiaens, *Imaging activation of two Ras isoforms simultaneously in a single cell*. *Chembiochem*, 2005. **6**(1): p. 78-85.
93. Violin, J.D., et al., *A genetically encoded fluorescent reporter reveals oscillatory phosphorylation by protein kinase C*. *J Cell Biol*, 2003. **161**(5): p. 899-909.
94. Imamura, H., et al., *Visualization of ATP levels inside single living cells with fluorescence resonance energy transfer-based genetically encoded indicators*. *Proc Natl Acad Sci U S A*, 2009. **106**(37): p. 15651-6.
95. Huang, R., et al., *Chemical genomics profiling of environmental chemical modulation of human nuclear receptors*. *Environ Health Perspect*, 2011. **119**(8): p. 1142-8.
96. Raymond, J. and D. Segre, *The effect of oxygen on biochemical networks and the evolution of complex life*. *Science*, 2006. **311**(5768): p. 1764-7.
97. Ma, Q., *Transcriptional responses to oxidative stress: pathological and toxicological implications*. *Pharmacol Ther*, 2010. **125**(3): p. 376-93.
98. Forman, H.J. and M. Torres, *Reactive oxygen species and cell signalling: respiratory burst in macrophage signalling*. *Am J Respir Crit Care Med*, 2002. **166**(12 Pt 2): p. S4-8.
99. Talalay, P., A.T. Dinkova-Kostova, and W.D. Holtzclaw, *Importance of phase 2 gene regulation in protection against electrophile and reactive oxygen toxicity and carcinogenesis*. *Adv Enzyme Regul*, 2003. **43**: p. 121-34.
100. James, L.P., P.R. Mayeux, and J.A. Hinson, *Acetaminophen-induced hepatotoxicity*. *Drug Metab Dispos*, 2003. **31**(12): p. 1499-506.
101. Barve, A., et al., *Gamma-tocopherol-enriched mixed tocopherol diet inhibits prostate carcinogenesis in TRAMP mice*. *Int J Cancer*, 2009. **124**(7): p. 1693-9.
102. Pool-Zobel, B., S. Veeriah, and F.D. Bohmer, *Modulation of xenobiotic metabolising enzymes by anticarcinogens -- focus on glutathione S-transferases and their role as targets of dietary chemoprevention in colorectal carcinogenesis*. *Mutat Res*, 2005. **591**(1-2): p. 74-92.
103. Kumaraguruparan, R., et al., *Chemoprevention of rat mammary carcinogenesis by black tea polyphenols: modulation of xenobiotic-metabolizing enzymes, oxidative stress, cell proliferation, apoptosis, and angiogenesis*. *Mol Carcinog*, 2007. **46**(9): p. 797-806.
104. Lee, S.B., et al., *Induction of the phase II detoxification enzyme NQO1 in hepatocarcinoma cells by lignans from the fruit of Schisandra chinensis through nuclear accumulation of Nrf2*. *Planta Med*, 2009. **75**(12): p. 1314-8.
105. Venugopal, R. and A.K. Jaiswal, *Nrf1 and Nrf2 positively and c-Fos and Fra1 negatively regulate the human antioxidant response element-mediated expression of NAD(P)H:quinone oxidoreductase1 gene*. *Proc Natl Acad Sci U S A*, 1996. **93**(25): p. 14960-5.
106. Ma, Q. and X. He, *Molecular basis of electrophilic and oxidative defense: promises and perils of Nrf2*. *Pharmacol Rev*, 2012. **64**(4): p. 1055-81.
107. Itoh, K., et al., *Keap1 represses nuclear activation of antioxidant responsive elements by Nrf2 through binding to the amino-terminal Neh2 domain*. *Genes Dev*, 1999. **13**(1): p. 76-86.
108. Talalay, P., M.J. De Long, and H.J. Prochaska, *Identification of a common chemical signal regulating the induction of enzymes that protect against chemical carcinogenesis*. *Proc Natl Acad Sci U S A*, 1988. **85**(21): p. 8261-5.
109. Dinkova-Kostova, A.T., et al., *Potency of Michael reaction acceptors as inducers of enzymes that protect against carcinogenesis depends on their reactivity with sulfhydryl groups*. *Proc Natl Acad Sci U S A*, 2001. **98**(6): p. 3404-9.
110. Zhang, D.D., et al., *Keap1 is a redox-regulated substrate adaptor protein for a Cul3-dependent ubiquitin ligase complex*. *Mol Cell Biol*, 2004. **24**(24): p. 10941-53.
111. Hong, F., M.L. Freeman, and D.C. Liebler, *Identification of sensor cysteines in human Keap1 modified by the cancer chemopreventive agent sulforaphane*. *Chem Res Toxicol*, 2005. **18**(12): p. 1917-26.
112. Rushmore, T.H., M.R. Morton, and C.B. Pickett, *The antioxidant responsive element. Activation by oxidative stress and identification of the DNA consensus sequence required for functional activity*. *J Biol Chem*, 1991. **266**(18): p. 11632-9.
113. Liu, J., et al., *Nrf2 protection against liver injury produced by various hepatotoxicants*. *Oxid Med Cell Longev*, 2013. **2013**: p. 305861.
114. Patterson, A.D., et al., *Disruption of Thioredoxin Reductase 1 Protects Mice from Acute Acetaminophen-Induced Hepatotoxicity through Enhanced NRF2 Activity*. *Chem Res Toxicol*, 2013.

115. Copple, I.M., et al., *The hepatotoxic metabolite of acetaminophen directly activates the Keap1-Nrf2 cell defense system*. Hepatology, 2008. **48**(4): p. 1292-301.
116. Kansanen, E., et al., *The Keap1-Nrf2 pathway: Mechanisms of activation and dysregulation in cancer*. Redox Biol, 2013. **1**(1): p. 45-49.
117. Shelton, P. and A.K. Jaiswal, *The transcription factor NF-E2-related factor 2 (Nrf2): a protooncogene?* FASEB J, 2013. **27**(2): p. 414-23.
118. Hetz, C., *The unfolded protein response: controlling cell fate decisions under ER stress and beyond*. Nat Rev Mol Cell Biol, 2012. **13**(2): p. 89-102.
119. Ron, D. and P. Walter, *Signal integration in the endoplasmic reticulum unfolded protein response*. Nat Rev Mol Cell Biol, 2007. **8**(7): p. 519-29.
120. Shen, J., et al., *ER stress regulation of ATF6 localization by dissociation of BiP/GRP78 binding and unmasking of Golgi localization signals*. Dev Cell, 2002. **3**(1): p. 99-111.
121. Harding, H.P., et al., *Regulated translation initiation controls stress-induced gene expression in mammalian cells*. Mol Cell, 2000. **6**(5): p. 1099-108.
122. Ameri, K. and A.L. Harris, *Activating transcription factor 4*. Int J Biochem Cell Biol, 2008. **40**(1): p. 14-21.
123. Travers, K.J., et al., *Functional and genomic analyses reveal an essential coordination between the unfolded protein response and ER-associated degradation*. Cell, 2000. **101**(3): p. 249-58.
124. Han, D., et al., *IRE1alpha kinase activation modes control alternate endoribonuclease outputs to determine divergent cell fates*. Cell, 2009. **138**(3): p. 562-75.
125. Kroemer, G., G. Marino, and B. Levine, *Autophagy and the integrated stress response*. Mol Cell, 2010. **40**(2): p. 280-93.
126. Kang, S.W., et al., *Substrate-specific translocational attenuation during ER stress defines a pre-emptive quality control pathway*. Cell, 2006. **127**(5): p. 999-1013.
127. Haze, K., et al., *Mammalian transcription factor ATF6 is synthesized as a transmembrane protein and activated by proteolysis in response to endoplasmic reticulum stress*. Mol Biol Cell, 1999. **10**(11): p. 3787-99.
128. Yamamoto, K., et al., *Transcriptional induction of mammalian ER quality control proteins is mediated by single or combined action of ATF6alpha and XBP1*. Dev Cell, 2007. **13**(3): p. 365-76.
129. Averous, J., et al., *Induction of CHOP expression by amino acid limitation requires both ATF4 expression and ATF2 phosphorylation*. J Biol Chem, 2004. **279**(7): p. 5288-97.
130. Zhang, H., et al., *Selective, potent blockade of the IRE1 and ATF6 pathways by 4-phenylbutyric acid analogues*. Br J Pharmacol, 2013. **170**(4): p. 822-34.
131. Ma, Y. and L.M. Hendershot, *Herp is dually regulated by both the endoplasmic reticulum stress-specific branch of the unfolded protein response and a branch that is shared with other cellular stress pathways*. J Biol Chem, 2004. **279**(14): p. 13792-9.
132. Yamaguchi, H. and H.G. Wang, *CHOP is involved in endoplasmic reticulum stress-induced apoptosis by enhancing DR5 expression in human carcinoma cells*. J Biol Chem, 2004. **279**(44): p. 45495-502.
133. Puthalakath, H., et al., *ER stress triggers apoptosis by activating BH3-only protein Bim*. Cell, 2007. **129**(7): p. 1337-49.
134. Back, S.H., et al., *Translation attenuation through eIF2alpha phosphorylation prevents oxidative stress and maintains the differentiated state in beta cells*. Cell Metab, 2009. **10**(1): p. 13-26.
135. Tamaki, N., et al., *CHOP deficiency attenuates cholestasis-induced liver fibrosis by reduction of hepatocyte injury*. Am J Physiol Gastrointest Liver Physiol, 2008. **294**(2): p. G498-505.
136. Hur, K.Y., et al., *IRE1alpha activation protects mice against acetaminophen-induced hepatotoxicity*. J Exp Med, 2012. **209**(2): p. 307-18.
137. Racanelli, V. and B. Rehermann, *The liver as an immunological organ*. Hepatology, 2006. **43**(2 Suppl 1): p. S54-62.
138. Tian, Z., Y. Chen, and B. Gao, *Natural killer cells in liver disease*. Hepatology, 2013. **57**(4): p. 1654-62.
139. Lukacs-Kornek, V. and D. Schuppan, *Dendritic cells in liver injury and fibrosis: shortcomings and promises*. J Hepatol, 2013. **59**(5): p. 1124-6.
140. Shaw, P.J., P.E. Ganey, and R.A. Roth, *Tumor necrosis factor alpha is a proximal mediator of synergistic hepatotoxicity from trovafloxacin/lipopolysaccharide coexposure*. The Journal of pharmacology and experimental therapeutics, 2009. **328**(1): p. 62-8.
141. Zou, W., et al., *Sulindac metabolism and synergy with tumor necrosis factor-alpha in a drug-inflammation interaction model of idiosyncratic liver injury*. The Journal of pharmacology and experimental therapeutics, 2009. **331**(1): p. 114-21.
142. Landstrom, M., *The TAK1-TRAF6 signalling pathway*. The international journal of biochemistry & cell biology, 2010. **42**(5): p. 585-9.
143. Dinarello, C.A., *Immunological and inflammatory functions of the interleukin-1 family*. Annual review of immunology, 2009. **27**: p. 519-50.

144. Corsini, A., et al., *Current challenges and controversies in drug-induced liver injury*. Drug safety : an international journal of medical toxicology and drug experience, 2012. **35**(12): p. 1099-117.
145. Eliceiri, K.W., et al., *Biological imaging software tools*. Nat Methods, 2012. **9**(7): p. 697-710.
146. Cosgrove, B.D., et al., *Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity*. Toxicology and applied pharmacology, 2009. **237**(3): p. 317-30.
147. Ramm, S. and A. Mally, *Role of drug-independent stress factors in liver injury associated with diclofenac intake*. Toxicology, 2013. **312C**: p. 83-96.
148. Kastan, M.B. and J. Bartek, *Cell-cycle checkpoints and cancer*. Nature, 2004. **432**(7015): p. 316-23.
149. Hartwell, L.H. and T.A. Weinert, *Checkpoints: controls that ensure the order of cell cycle events*. Science, 1989. **246**(4930): p. 629-34.
150. Lagerwerf, S., et al., *DNA damage response and transcription*. DNA Repair (Amst), 2011. **10**(7): p. 743-50.
151. Shiloh, Y., *ATM and related protein kinases: safeguarding genome integrity*. Nat Rev Cancer, 2003. **3**(3): p. 155-68.
152. FitzGerald, J.E., M. Grenon, and N.F. Lowndes, *53BP1: function and mechanisms of focal recruitment*. Biochem Soc Trans, 2009. **37**(Pt 4): p. 897-904.
153. Zhou, B.B. and S.J. Elledge, *The DNA damage response: putting checkpoints in perspective*. Nature, 2000. **408**(6811): p. 433-9.
154. Li, L. and L. Zou, *Sensing, signalling, and responding to DNA damage: organization of the checkpoint pathways in mammalian cells*. J Cell Biochem, 2005. **94**(2): p. 298-306.
155. Banin, S., et al., *Enhanced phosphorylation of p53 by ATM in response to DNA damage*. Science, 1998. **281**(5383): p. 1674-7.
156. Khosravi, R., et al., *Rapid ATM-dependent phosphorylation of MDM2 precedes p53 accumulation in response to DNA damage*. Proc Natl Acad Sci U S A, 1999. **96**(26): p. 14973-7.
157. Riley, T., et al., *Transcriptional control of human p53-regulated genes*. Nat Rev Mol Cell Biol, 2008. **9**(5): p. 402-12.
158. Yu, J. and L. Zhang, *No PUMA, no death: implications for p53-dependent apoptosis*. Cancer Cell, 2003. **4**(4): p. 248-9.
159. Chipuk, J.E., et al., *PUMA couples the nuclear and cytoplasmic proapoptotic function of p53*. Science, 2005. **309**(5741): p. 1732-5.
160. Vousden, K.H. and C. Prives, *Blinded by the Light: The Growing Complexity of p53*. Cell, 2009. **137**(3): p. 413-31.
161. Brady, C.A. and L.D. Attardi, *p53 at a glance*. J Cell Sci, 2010. **123**(Pt 15): p. 2527-32.
162. Bieganski, K.T. and L.D. Attardi, *Deconstructing p53 transcriptional networks in tumor suppression*. Trends Cell Biol, 2012. **22**(2): p. 97-106.
163. Liang, S.H. and M.F. Clarke, *Regulation of p53 localization*. Eur J Biochem, 2001. **268**(10): p. 2779-83.
164. Tao, W. and A.J. Levine, *Nucleocytoplasmic shuttling of oncoprotein Hdm2 is required for Hdm2-mediated degradation of p53*. Proc Natl Acad Sci U S A, 1999. **96**(6): p. 3077-80.
165. Jayaraman, L. and C. Prives, *Covalent and noncovalent modifiers of the p53 protein*. Cell Mol Life Sci, 1999. **55**(1): p. 76-87.
166. Tibbetts, R.S., et al., *A role for ATR in the DNA damage-induced phosphorylation of p53*. Genes Dev, 1999. **13**(2): p. 152-7.
167. Shieh, S.Y., et al., *DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2*. Cell, 1997. **91**(3): p. 325-34.
168. Sakaguchi, K., et al., *Damage-mediated phosphorylation of human p53 threonine 18 through a cascade mediated by a casein 1-like kinase. Effect on Mdm2 binding*. J Biol Chem, 2000. **275**(13): p. 9278-83.
169. Harper, J.W. and S.J. Elledge, *The DNA damage response: ten years after*. Mol Cell, 2007. **28**(5): p. 739-45.
170. Bartek, J., J. Bartkova, and J. Lukas, *DNA damage signalling guards against activated oncogenes and tumour progression*. Oncogene, 2007. **26**(56): p. 7773-9.
171. Moudry, P., et al., *Nucleoporin NUP153 guards genome integrity by promoting nuclear import of 53BP1*. Cell Death Differ, 2012. **19**(5): p. 798-807.
172. Levav-Cohen, Y., S. Haupt, and Y. Haupt, *Mdm2 in growth signalling and cancer*. Growth Factors, 2005. **23**(3): p. 183-92.
173. Lahav, G., *Oscillations by the p53-Mdm2 feedback loop*. Adv Exp Med Biol, 2008. **641**: p. 28-38.
174. Westerheide, S.D. and R.I. Morimoto, *Heat shock response modulators as therapeutic tools for diseases of protein conformation*. J Biol Chem, 2005. **280**(39): p. 33097-100.
175. Voellmy, R. and F. Boellmann, *Chaperone regulation of the heat shock protein response*. Adv Exp Med Biol, 2007. **594**: p. 89-99.

176. Kampinga, H.H., et al., *Guidelines for the nomenclature of the human heat shock proteins*. Cell Stress Chaperones, 2009. **14**(1): p. 105-11.
177. Simmons, S.O., C.Y. Fan, and R. Ramabhadran, *Cellular stress response pathway system as a sentinel ensemble in toxicological screening*. Toxicol Sci, 2009. **111**(2): p. 202-25.
178. Gunther, V., et al., *A conserved cysteine cluster, essential for transcriptional activity, mediates homodimerization of human metal-responsive transcription factor-1 (MTF-1)*. Biochim Biophys Acta, 2012. **1823**(2): p. 476-83.
179. Carpena, E., G. Andreani, and G. Isani, *Metallothionein functions and structural characteristics*. J Trace Elem Med Biol, 2007. **21 Suppl 1**: p. 35-9.
180. Wang, Y., et al., *Metal-responsive transcription factor-1 (MTF-1) is essential for embryonic liver development and heavy metal detoxification in the adult liver*. FASEB J, 2004. **18**(10): p. 1071-9.
181. Lee, K.A., R.A. Roth, and J.J. LaPres, *Hypoxia, drug therapy and toxicity*. Pharmacol Ther, 2007. **113**(2): p. 229-46.
182. Li, Y., et al., *HUMMR, a hypoxia- and HIF-1alpha-inducible protein, alters mitochondrial distribution and transport*. J Cell Biol, 2009. **185**(6): p. 1065-81.
183. Sparkenbaugh, E.M., et al., *The role of hypoxia-inducible factor-1alpha in acetaminophen hepatotoxicity*. J Pharmacol Exp Ther, 2011. **338**(2): p. 492-502.
184. Li, F., et al., *Human PXR modulates hepatotoxicity associated with rifampicin and isoniazid co-therapy*. Nat Med, 2013. **19**(4): p. 418-20.
185. Picard, M., et al., *Mitochondrial morphology transitions and functions: implications for retrograde signalling?* Am J Physiol Regul Integr Comp Physiol, 2013. **304**(6): p. R393-406.
186. Rimessi, A., et al., *Perturbed mitochondrial Ca signals as causes or consequences of mitophagy induction*. Autophagy, 2013. **9**(11).
187. Lenna, S. and M. Trojanowska, *The role of endoplasmic reticulum stress and the unfolded protein response in fibrosis*. Curr Opin Rheumatol, 2012. **24**(6): p. 663-8.
188. Huveneers, S., et al., *Integrins uncouple Src-induced morphological and oncogenic transformation*. J Biol Chem, 2008. **283**(19): p. 13243-51.
189. van de Water, B., et al., *Cleavage of the actin-capping protein alpha -adducin at Asp-Asp-Ser-Asp633-Ala by caspase-3 is preceded by its phosphorylation on serine 726 in cisplatin-induced apoptosis of renal epithelial cells*. J Biol Chem, 2000. **275**(33): p. 25805-13.
190. Schneider, C.A., W.S. Rasband, and K.W. Eliceiri, *NIH Image to ImageJ: 25 years of image analysis*. Nat Methods, 2012. **9**(7): p. 671-5.
191. Carpenter, A.E., et al., *CellProfiler: image analysis software for identifying and quantifying cell phenotypes*. Genome Biol, 2006. **7**(10): p. R100.
192. *The HDF Group Hierarchical data format version 5*. 2000-2010.
193. Di, Z., et al., *Automated analysis of NF-kappaB nuclear translocation kinetics in high-throughput screening*. PLoS One, 2012. **7**(12): p. e52337.
194. Sommer, C., et al., *CellH5: a format for data exchange in high-content screening*. Bioinformatics, 2013. **29**(12): p. 1580-2.
195. Dougherty, M.T., et al., *Unifying Biological Image Formats with HDF5*. Commun ACM, 2009. **52**(10): p. 42-47.
196. Warren, S.C., et al., *Rapid global fitting of large fluorescence lifetime imaging microscopy datasets*. PLoS One, 2013. **8**(8): p. e70687.
197. Michael R. Berthold, N.C., Fabian Dill, Thomas R. Gabriel, Tobias Kötter, Thorsten Meinl, Peter Ohl, Christoph Sieb, Kilian Thiel, Bernd Wiswedel, *KNIME: The Konstanz Information Miner*. Studies in Classification, Data Analysis, and Knowledge Organization (GfKL 2007). Springer.
198. ToxCast™. <http://www.epa.gov/ncct/toxcast/>. Available from: <http://www.epa.gov/ncct/toxcast/>.
199. Yates, M.S., et al., *Pharmacodynamic characterization of chemopreventive triterpenoids as exceptionally potent inducers of Nrf2-regulated genes*. Mol Cancer Ther, 2007. **6**(1): p. 154-62.
200. Laine, L., et al., *How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial*. The American journal of gastroenterology, 2009. **104**(2): p. 356-62.
201. Yano, A., et al., *Involvement of immune-related factors in diclofenac-induced acute liver injury in mice*. Toxicology, 2012. **293**(1-3): p. 107-14.
202. Basak, S., M. Behar, and A. Hoffmann, *Lessons from mathematically modeling the NF-kappaB pathway*. Immunol Rev, 2012. **246**(1): p. 221-38.
203. Jain, A., et al., *p62/SQSTM1 is a target gene for transcription factor NRF2 and creates a positive feedback loop by inducing antioxidant response element-driven gene transcription*. J Biol Chem, 2010. **285**(29): p. 22576-91.
204. Li, Y., J.D. Paonessa, and Y. Zhang, *Mechanism of chemical activation of Nrf2*. PLoS One, 2012. **7**(4): p. e35122.

205. McMahon, M., et al., *Redox-regulated turnover of Nrf2 is determined by at least two separate protein domains, the redox-sensitive Neh2 degron and the redox-insensitive Neh6 degron*. J Biol Chem, 2004. **279**(30): p. 31556-67.
206. Westerink, W.M. and W.G. Schoonen, *Phase II enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells*. Toxicol In Vitro, 2007. **21**(8): p. 1592-602.
207. Westerink, W.M. and W.G. Schoonen, *Cytochrome P450 enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells*. Toxicol In Vitro, 2007. **21**(8): p. 1581-91.
208. Nakamura, K., et al., *Expression of albumin and cytochrome P450 enzymes in HepG2 cells cultured with a nanotechnology-based culture plate with microfabricated scaffold*. J Toxicol Sci, 2011. **36**(5): p. 625-33.
209. Katsuda, T., Y. Sakai, and T. Ochiya, *Induced pluripotent stem cell-derived hepatocytes as an alternative to human adult hepatocytes*. J Stem Cells, 2012. **7**(1): p. 1-17.
210. Tox21. <http://www.epa.gov/ncct/Tox21/>. Available from: <http://www.epa.gov/ncct/Tox21/>.
211. Vinken, M., *The adverse outcome pathway concept: a pragmatic tool in toxicology*. Toxicology, 2013. **312**: p. 158-65.
212. Venugopal, R. and A.K. Jaiswal, *Nrf2 and Nrf1 in association with Jun proteins regulate antioxidant response element-mediated expression and coordinated induction of genes encoding detoxifying enzymes*. Oncogene, 1998. **17**(24): p. 3145-56.
213. Kim, R., et al., *Role of the unfolded protein response in cell death*. Apoptosis, 2006. **11**(1): p. 5-13.
214. Reed, M., et al., *The C-terminal domain of p53 recognizes DNA damaged by ionizing radiation*. Proc Natl Acad Sci U S A, 1995. **92**(21): p. 9455-9.
215. Girinsky, T., et al., *Attenuated response of p53 and p21 in primary cultures of human prostatic epithelial cells exposed to DNA-damaging agents*. Cancer Res, 1995. **55**(17): p. 3726-31.
216. Mazur, W., et al., *Cell-specific elevation of NRF2 and sulfiredoxin-1 as markers of oxidative stress in the lungs of idiopathic pulmonary fibrosis and non-specific interstitial pneumonia*. APMIS, 2010. **118**(9): p. 703-12.
217. Herpers, B., et al., *Activation of the Nrf2 response by intrinsic hepatotoxic drugs correlates with suppression of NF-kappaB activation and sensitizes toward TNFalpha-induced cytotoxicity*. Arch Toxicol, 2015.
218. Takayanagi, S., et al., *Gene regulatory network of unfolded protein response genes in endoplasmic reticulum stress*. Cell Stress Chaperones, 2013. **18**(1): p. 11-23.
219. Reinke, V. and G. Lozano, *Differential activation of p53 targets in cells treated with ultraviolet radiation that undergo both apoptosis and growth arrest*. Radiat Res, 1997. **148**(2): p. 115-22.
220. d'Adda di Fagagna, F., et al., *A DNA damage checkpoint response in telomere-initiated senescence*. Nature, 2003. **426**(6963): p. 194-8.
221. Knasmuller, S., et al., *Use of human-derived liver cell lines for the detection of environmental and dietary genotoxicants; current state of knowledge*. Toxicology, 2004. **198**(1-3): p. 315-28.
222. Maness, S.C., D.P. McDonnell, and K.W. Gaido, *Inhibition of androgen receptor-dependent transcriptional activity by DDT isomers and methoxychlor in HepG2 human hepatoma cells*. Toxicol Appl Pharmacol, 1998. **151**(1): p. 135-42.
223. Lin, Z. and Y. Will, *Evaluation of drugs with specific organ toxicities in organ-specific cell lines*. Toxicol Sci, 2012. **126**(1): p. 114-27.
224. Purschke, M., et al., *Phototoxicity of Hoechst 33342 in time-lapse fluorescence microscopy*. Photochem Photobiol Sci, 2010. **9**(12): p. 1634-9.
225. Du, G., et al., *Spatial dynamics of DNA damage response protein foci along the ion trajectory of high-LET particles*. Radiat Res, 2011. **176**(6): p. 706-15.
226. Wickham, H., *ggplot2: elegant graphics for data analysis*. 2009.
227. Gaujoux, R. and C. Seoighe, *A flexible R package for nonnegative matrix factorization*. BMC Bioinformatics, 2010. **11**: p. 367.
228. Irizarry, R.A., et al., *Exploration, normalization, and summaries of high density oligonucleotide array probe level data*. Biostatistics, 2003. **4**(2): p. 249-64.
229. Itoh, K., K.I. Tong, and M. Yamamoto, *Molecular mechanism activating Nrf2-Keap1 pathway in regulation of adaptive response to electrophiles*. Free Radic Biol Med, 2004. **36**(10): p. 1208-13.
230. Hetz, C., E. Chevet, and S.A. Oakes, *Proteostasis control by the unfolded protein response*. Nat Cell Biol, 2015. **17**(7): p. 829-38.
231. Gulow, K., D. Bienert, and I.G. Haas, *BiP is feed-back regulated by control of protein translation efficiency*. J Cell Sci, 2002. **115**(Pt 11): p. 2443-52.
232. Lee, D.H., et al., *Dephosphorylation enables the recruitment of 53BP1 to double-strand DNA breaks*. Mol Cell, 2014. **54**(3): p. 512-25.
233. Yang, L., et al., *Neuroprotective effects of the triterpenoid, CDDO methyl amide, a potent inducer of Nrf2-mediated transcription*. PLoS One, 2009. **4**(6): p. e5757.

234. Li, L. and G.K. Hu, *Pink1 protects cortical neurons from thapsigargin-induced oxidative stress and neuronal apoptosis*. *Biosci Rep*, 2015. **35**(1).
235. Yoshida, H., *Unconventional splicing of XBP-1 mRNA in the unfolded protein response*. *Antioxid Redox Signal*, 2007. **9**(12): p. 2323-33.
236. Wink, S., et al., *Quantitative high content imaging of cellular adaptive stress response pathways in toxicity for chemical safety assessment*. *Chem Res Toxicol*, 2014. **27**(3): p. 338-55.
237. Limonciel, A., et al., *Transcriptomics hit the target: Monitoring of ligand-activated and stress response pathways for chemical testing*. *Toxicol In Vitro*, 2015.
238. Fredriksson, L., et al., *Drug-induced endoplasmic reticulum and oxidative stress responses independently sensitize toward TNF α -mediated hepatotoxicity*. *Toxicol Sci*, 2014. **140**(1): p. 144-59.
239. Loo, L.H., L.F. Wu, and S.J. Altschuler, *Image-based multivariate profiling of drug responses from single cells*. *Nat Methods*, 2007. **4**(5): p. 445-53.
240. Persson, M., et al., *A high content screening assay to predict human drug-induced liver injury during drug discovery*. *J Pharmacol Toxicol Methods*, 2013. **68**(3): p. 302-13.
241. Garside, H., et al., *Evaluation of the use of imaging parameters for the detection of compound-induced hepatotoxicity in 384-well cultures of HepG2 cells and cryopreserved primary human hepatocytes*. *Toxicol In Vitro*, 2014. **28**(2): p. 171-81.
242. Roth, R.A. and P.E. Ganey, *Animal models of idiosyncratic drug-induced liver injury--current status*. *Crit Rev Toxicol*, 2011. **41**(9): p. 723-39.
243. Shaw, P.J., et al., *Lipopolysaccharide and trovafloxacin coexposure in mice causes idiosyncrasy-like liver injury dependent on tumor necrosis factor- α* . *Toxicol Sci*, 2007. **100**(1): p. 259-66.
244. Cosgrove, B.D., et al., *Synergistic drug-cytokine induction of hepatocellular death as an in vitro approach for the study of inflammation-associated idiosyncratic drug hepatotoxicity*. *Toxicol Appl Pharmacol*, 2009. **237**(3): p. 317-30.
245. Lu, J., et al., *Amiodarone exposure during modest inflammation induces idiosyncrasy-like liver injury in rats: role of tumor necrosis factor- α* . *Toxicol Sci*, 2012. **125**(1): p. 126-33.
246. Cosgrove, B.D., et al., *Cytokine-associated drug toxicity in human hepatocytes is associated with signalling network dysregulation*. *Mol Biosyst*, 2010. **6**(7): p. 1195-206.
247. Cui, Y. and R.S. Paules, *Use of transcriptomics in understanding mechanisms of drug-induced toxicity*. *Pharmacogenomics*, 2010. **11**(4): p. 573-85.
248. Jaiswal, A.K., *Nrf2 signalling in coordinated activation of antioxidant gene expression*. *Free Radic Biol Med*, 2004. **36**(10): p. 1199-207.
249. Kobayashi, A., et al., *Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2*. *Mol Cell Biol*, 2004. **24**(16): p. 7130-9.
250. Okawa, H., et al., *Hepatocyte-specific deletion of the keap1 gene activates Nrf2 and confers potent resistance against acute drug toxicity*. *Biochem Biophys Res Commun*, 2006. **339**(1): p. 79-88.
251. Woehlbier, U. and C. Hetz, *Modulating stress responses by the UPRosome: a matter of life and death*. *Trends Biochem Sci*, 2011. **36**(6): p. 329-37.
252. Dara, L., C. Ji, and N. Kaplowitz, *The contribution of endoplasmic reticulum stress to liver diseases*. *Hepatology*, 2011. **53**(5): p. 1752-63.
253. van Kesteren, P.C., et al., *Deregulation of cancer-related pathways in primary hepatocytes derived from DNA repair-deficient Xpa $^{-/-}$ p53 $^{+/-}$ mice upon exposure to benzo[a]pyrene*. *Toxicol Sci*, 2011. **123**(1): p. 123-32.
254. Hochberg, Y. and Y. Benjamini, *More powerful procedures for multiple significance testing*. *Stat Med*, 1990. **9**(7): p. 811-8.
255. Saeed, A.I., et al., *TM4: a free, open-source system for microarray data management and analysis*. *Biotechniques*, 2003. **34**(2): p. 374-8.
256. Edgar, R., M. Domrachev, and A.E. Lash, *Gene Expression Omnibus: NCBI gene expression and hybridization array data repository*. *Nucleic Acids Res*, 2002. **30**(1): p. 207-10.
257. Huber, W., et al., *Variance stabilization applied to microarray data calibration and to the quantification of differential expression*. *Bioinformatics*, 2002. **18 Suppl 1**: p. S96-104.
258. Wolfinger, R.D., et al., *Assessing gene significance from cDNA microarray expression data via mixed models*. *J Comput Biol*, 2001. **8**(6): p. 625-37.
259. Smyth, G.K., J. Michaud, and H.S. Scott, *Use of within-array replicate spots for assessing differential expression in microarray experiments*. *Bioinformatics*, 2005. **21**(9): p. 2067-75.
260. Smyth, G.K., *Linear models and empirical bayes methods for assessing differential expression in microarray experiments*. *Stat Appl Genet Mol Biol*, 2004. **3**: p. Article3.
261. Puigvert, J.C., et al., *High-throughput live cell imaging of apoptosis*. *Curr Protoc Cell Biol*, 2010. **Chapter 18**: p. Unit 18 10 1-13.

262. van De Water, B., et al., *Distinct endoplasmic reticulum signalling pathways regulate apoptotic and necrotic cell death following iodoacetamide treatment*. *Chem Res Toxicol*, 1999. **12**(10): p. 943-51.
263. Xu, J.J., et al., *Cellular imaging predictions of clinical drug-induced liver injury*. *Toxicol Sci*, 2008. **105**(1): p. 97-105.
264. Chen, M., et al., *FDA-approved drug labeling for the study of drug-induced liver injury*. *Drug Discov Today*, 2011. **16**(15-16): p. 697-703.
265. Zou, W., et al., *Sulindac metabolism and synergy with tumor necrosis factor-alpha in a drug-inflammation interaction model of idiosyncratic liver injury*. *J Pharmacol Exp Ther*, 2009. **331**(1): p. 114-21.
266. Soriano, F.X., et al., *Transcriptional regulation of the AP-1 and Nrf2 target gene sulfiredoxin*. *Mol Cells*, 2009. **27**(3): p. 279-82.
267. Cullinan, S.B. and J.A. Diehl, *Coordination of ER and oxidative stress signalling: the PERK/Nrf2 signalling pathway*. *Int J Biochem Cell Biol*, 2006. **38**(3): p. 317-32.
268. Boyce, M., et al., *A selective inhibitor of eIF2alpha dephosphorylation protects cells from ER stress*. *Science*, 2005. **307**(5711): p. 935-9.
269. Deng, X., et al., *Gene expression profiles in livers from diclofenac-treated rats reveal intestinal bacteria-dependent and -independent pathways associated with liver injury*. *J Pharmacol Exp Ther*, 2008. **327**(3): p. 634-44.
270. Leeder, J.S., *Mechanisms of idiosyncratic hypersensitivity reactions to antiepileptic drugs*. *Epilepsia*, 1998. **39** **Suppl 7**: p. S8-16.
271. Stricker, B.H., et al., *Ketoconazole-associated hepatic injury. A clinicopathological study of 55 cases*. *J Hepatol*, 1986. **3**(3): p. 399-406.
272. West, S.G., *Methotrexate hepatotoxicity*. *Rheum Dis Clin North Am*, 1997. **23**(4): p. 883-915.
273. Choi, S., *Nefazodone (Serzone) withdrawn because of hepatotoxicity*. *CMAJ*, 2003. **169**(11): p. 1187.
274. Parsyan, A., et al., *mRNA helicases: the tacticians of translational control*. *Nat Rev Mol Cell Biol*, 2011. **12**(4): p. 235-45.
275. Jackson, R.J., C.U. Hellen, and T.V. Pestova, *The mechanism of eukaryotic translation initiation and principles of its regulation*. *Nat Rev Mol Cell Biol*, 2010. **11**(2): p. 113-27.
276. Holcik, M., et al., *A new internal-ribosome-entry-site motif potentiates XIAP-mediated cytoprotection*. *Nat Cell Biol*, 1999. **1**(3): p. 190-2.
277. Coldwell, M.J., et al., *Initiation of Apaf-1 translation by internal ribosome entry*. *Oncogene*, 2000. **19**(7): p. 899-905.
278. Cantoni, L., et al., *Induction of hepatic heme oxygenase-1 by diclofenac in rodents: role of oxidative stress and cytochrome P-450 activity*. *J Hepatol*, 2003. **38**(6): p. 776-83.
279. Gomez-Lechon, M.J., et al., *Diclofenac induces apoptosis in hepatocytes by alteration of mitochondrial function and generation of ROS*. *Biochem Pharmacol*, 2003. **66**(11): p. 2155-67.
280. Santos, N.A., et al., *Involvement of oxidative stress in the hepatotoxicity induced by aromatic antiepileptic drugs*. *Toxicol In Vitro*, 2008. **22**(8): p. 1820-4.
281. Han, D., et al., *Regulation of drug-induced liver injury by signal transduction pathways: critical role of mitochondria*. *Trends in Pharmacological Sciences*, 2013. **34**(4): p. 243-253.
282. Steuerwald, N.M., et al., *Profiles of serum cytokines in acute drug-induced liver injury and their prognostic significance*. *PLoS One*, 2013. **8**(12): p. e81974.
283. Shaw, P.J., et al., *Lipopolysaccharide and trovafloxacin coexposure in mice causes idiosyncrasy-like liver injury dependent on tumor necrosis factor-alpha*. *Toxicological Sciences*, 2007. **100**(1): p. 259-66.
284. Mercurio, F., et al., *IKK-1 and IKK-2: cytokine-activated IkkappaB kinases essential for NF-kappaB activation*. *Science*, 1997. **278**(5339): p. 860-6.
285. Liu, Z.G., et al., *Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kappaB activation prevents cell death*. *Cell*, 1996. **87**(3): p. 565-76.
286. Leung, L., A.S. Kalgutkar, and R.S. Obach, *Metabolic activation in drug-induced liver injury*. *Drug Metab Rev*, 2012. **44**(1): p. 18-33.
287. Li, J., et al., *Stabilization of Nrf2 by tBHQ confers protection against oxidative stress-induced cell death in human neural stem cells*. *Toxicological Sciences*, 2005. **83**(2): p. 313-28.
288. Liu, F., et al., *Increased susceptibility of Nrf2-null mice to 1-bromopropane-induced hepatotoxicity*. *Toxicological Sciences*, 2010. **115**(2): p. 596-606.
289. Chen, X.L., et al., *Activation of Nrf2/ARE pathway protects endothelial cells from oxidant injury and inhibits inflammatory gene expression*. *Am J Physiol Heart Circ Physiol*, 2006. **290**(5): p. H1862-70.
290. Ashburner, M., et al., *Gene ontology: tool for the unification of biology. The Gene Ontology Consortium*. *Nature Genetics*, 2000. **25**(1): p. 25-9.
291. Carbon, S., et al., *AmiGO: online access to ontology and annotation data*. *Bioinformatics*, 2009. **25**(2): p. 288-9.

292. Liberzon, A., et al., *Molecular signatures database (MSigDB) 3.0*. Bioinformatics, 2011. **27**(12): p. 1739-40.
293. Kanehisa, M., et al., *Data, information, knowledge and principle: back to metabolism in KEGG*. Nucleic acids research, 2014. **42**(Database issue): p. D199-205.
294. Croft, D., et al., *The Reactome pathway knowledgebase*. Nucleic Acids Research, 2014. **42**(Database issue): p. D472-7.
295. Qian, Z., Y.D. Cai, and Y. Li, *Automatic transcription factor classifier based on functional domain composition*. Biochemical and Biophysical Research Communications, 2006. **347**(1): p. 141-4.
296. Di, Z., et al., *Automated Analysis of NF- κ B Nuclear Translocation Kinetics in High-Throughput Screening*. PLoS One, 2012. **7**(12): p. e52337.
297. Yu, M., et al., *Nuclear factor p65 interacts with Keap1 to repress the Nrf2-ARE pathway*. Cellular Signalling, 2011. **23**(5): p. 883-892.
298. Liu, G.H., J. Qu, and X. Shen, *NF-kappaB/p65 antagonizes Nrf2-ARE pathway by depriving CBP from Nrf2 and facilitating recruitment of HDAC3 to MafK*. Biochimica et biophysica acta, 2008. **1783**(5): p. 713-27.
299. Boess, F., et al., *Gene expression in two hepatic cell lines, cultured primary hepatocytes, and liver slices compared to the in vivo liver gene expression in rats: possible implications for toxicogenomics use of in vitro systems*. Toxicological sciences : an official journal of the Society of Toxicology, 2003. **73**(2): p. 386-402.
300. Rushworth, S.A., S. Shah, and D.J. MacEwan, *TNF mediates the sustained activation of Nrf2 in human monocytes*. Journal of immunology, 2011. **187**(2): p. 702-7.
301. Hsu, H., et al., *TRADD-TRAF2 and TRADD-FADD interactions define two distinct TNF receptor 1 signal transduction pathways*. Cell, 1996. **84**(2): p. 299-308.
302. Sano, R. and J.C. Reed, *ER stress-induced cell death mechanisms*. Biochimica et biophysica acta, 2013. **1833**(12): p. 3460-70.
303. Hutti, J.E., et al., *IkappaB kinase beta phosphorylates the K63 deubiquitinase A20 to cause feedback inhibition of the NF-kappaB pathway*. Molecular and Cellular Biology, 2007. **27**(21): p. 7451-61.
304. Hinz, M. and C. Scheidereit, *The IkappaB kinase complex in NF-kappaB regulation and beyond*. EMBO Rep, 2014. **15**(1): p. 46-61.
305. Hadi, M., et al., *AMAP, the alleged non-toxic isomer of acetaminophen, is toxic in rat and human liver*. Archives of Toxicology, 2013. **87**(1): p. 155-165.
306. Cheng, J., et al., *CYP2E1-dependent elevation of serum cholesterol, triglycerides, and hepatic bile acids by isoniazid*. Toxicology and Applied Pharmacology, 2013. **266**(2): p. 245-253.
307. Foster, J.R., et al., *Differential Effect of Troglitazone on the Human Bile Acid Transporters, MRP2 and BSEP, in the PXB Hepatic Chimeric Mouse*. Toxicol Pathol, 2012.
308. Malinen, M.M., et al., *Peptide nanofiber hydrogel induces formation of bile canaliculi structures in three-dimensional hepatic cell culture*. Tissue engineering. Part A, 2012. **18**(23-24): p. 2418-25.
309. Raschi, E. and F. De Ponti, *Drug- and herb-induced liver injury: Progress, current challenges and emerging signals of post-marketing risk*. World J Hepatol, 2015. **7**(13): p. 1761-71.
310. Tang, S., et al., *Cytochrome P450 2E1 gene polymorphisms/haplotypes and anti-tuberculosis drug-induced hepatitis in a Chinese cohort*. PLoS One, 2013. **8**(2): p. e57526.
311. Ramachandran, R. and S. Kakar, *Histological patterns in drug-induced liver disease*. J Clin Pathol, 2009. **62**(6): p. 481-92.
312. Adeleye, Y., et al., *Implementing Toxicity Testing in the 21st Century (TT21C): Making safety decisions using toxicity pathways, and progress in a prototype risk assessment*. Toxicology, 2015. **332**: p. 102-11.
313. Park, S., Y.J. Choi, and B.H. Lee, *In vitro validation of drug-induced phospholipidosis*. J Toxicol Sci, 2012. **37**(2): p. 261-7.
314. Chatterjee, S., et al., *Hepatocyte-based in vitro model for assessment of drug-induced cholestasis*. Toxicol Appl Pharmacol, 2014. **274**(1): p. 124-36.
315. Dick, S.H., L.A. Tremere, and D.D. Rasmuson, *Calcitonin gene-related peptide and neuropeptide Y in the raccoon cuneate nucleus*. Brain Res Bull, 1998. **47**(4): p. 387-91.
316. Liu, Y., et al., *Role for the endoplasmic reticulum stress sensor IRE1alpha in liver regenerative responses*. J Hepatol, 2015. **62**(3): p. 590-8.
317. Mulder, J.E., et al., *The impact of chronic Aflatoxin B1 exposure and p53 genotype on base excision repair in mouse lung and liver*. Mutat Res, 2015. **773**: p. 63-8.
318. Bhat, A.H., et al., *Oxidative stress, mitochondrial dysfunction and neurodegenerative diseases; a mechanistic insight*. Biomed Pharmacother, 2015. **74**: p. 101-10.
319. Kaufman, R.J., *Orchestrating the unfolded protein response in health and disease*. J Clin Invest, 2002. **110**(10): p. 1389-98.
320. Ma, Y. and L.M. Hendershot, *The unfolding tale of the unfolded protein response*. Cell, 2001. **107**(7): p. 827-30.
321. Brenner, C., et al., *Decoding cell death signals in liver inflammation*. J Hepatol, 2013. **59**(3): p. 583-94.

322. Nagy, T., et al., *Inhibition of Glutathione S-Transferase by Ethacrynic Acid Augments Ischemia-Reperfusion Damage and Apoptosis and Attenuates the Positive Effect of Ischemic Postconditioning in a Bilateral Acute Hindlimb Ischemia Rat Model*. *J Vasc Res*, 2015. **52**(1): p. 53-61.
323. Suresh Kumar, G., et al., *Mitomycin C-DNA adducts generated by DT-diaphorase. Revised mechanism of the enzymatic reductive activation of mitomycin C*. *Biochemistry*, 1997. **36**(46): p. 14128-36.
324. Kim, J.A., et al., *Real-time concurrent monitoring of apoptosis, cytosolic calcium, and mitochondria permeability transition for hypermulticolor high-content screening of drug-induced mitochondrial dysfunction-mediated hepatotoxicity*. *Toxicol Lett*, 2012. **214**(2): p. 175-81.
325. Jones, T.R., et al., *CellProfiler Analyst: data exploration and analysis software for complex image-based screens*. *BMC Bioinformatics*, 2008. **9**: p. 482.
326. Di, Z., et al., *Ultra high content image analysis and phenotype profiling of 3D cultured micro-tissues*. *PLoS One*, 2014. **9**(10): p. e109688.
327. Goldring, C.E., et al., *Activation of hepatic Nrf2 in vivo by acetaminophen in CD-1 mice*. *Hepatology*, 2004. **39**(5): p. 1267-76.
328. Stephens, C., R.J. Andrade, and M.I. Lucena, *Mechanisms of drug-induced liver injury*. *Curr Opin Allergy Clin Immunol*, 2014. **14**(4): p. 286-92.
329. Allan, C., et al., *OMERO: flexible, model-driven data management for experimental biology*. *Nat Methods*, 2012. **9**(3): p. 245-53.
330. Schindelin, J., et al., *Fiji: an open-source platform for biological-image analysis*. *Nat Methods*, 2012. **9**(7): p. 676-82.
331. Forslund, E., et al., *Novel Microchip-Based Tools Facilitating Live Cell Imaging and Assessment of Functional Heterogeneity within NK Cell Populations*. *Front Immunol*, 2012. **3**: p. 300.
332. Pauwels, E., et al., *A probabilistic model for cell population phenotyping using HCS data*. *PLoS One*, 2012. **7**(8): p. e42715.
333. van Roosmalen, W., et al., *Tumor cell migration screen identifies SRPK1 as breast cancer metastasis determinant*. *J Clin Invest*, 2015. **125**(4): p. 1648-64.
334. Uzi, D., et al., *CHOP is a critical regulator of acetaminophen-induced hepatotoxicity*. *J Hepatol*, 2013. **59**(3): p. 495-503.
335. Pfaffenbach, K.T., et al., *Linking endoplasmic reticulum stress to cell death in hepatocytes: roles of C/EBP homologous protein and chemical chaperones in palmitate-mediated cell death*. *Am J Physiol Endocrinol Metab*, 2010. **298**(5): p. E1027-35.
336. Beggs, K.M., et al., *Trovafloxacin-induced replication stress sensitizes HepG2 cells to tumor necrosis factor-alpha-induced cytotoxicity mediated by extracellular signal-regulated kinase and ataxia telangiectasia and Rad3-related*. *Toxicology*, 2015. **331**: p. 35-46.
337. Alkreathy, H.M., et al., *CCl4 induced genotoxicity and DNA oxidative damages in rats: hepatoprotective effect of *Sonchus arvensis**. *BMC Complement Altern Med*, 2014. **14**: p. 452.

List of abbreviations

ADR: Adverse Drug Reaction
AMAP: 3'-hydroxyacetanilide
AMI: amiodarone
AOP: Adverse Outcome Pathway
APAP: acetaminophen/ paracetamol
BAC: Bacterial Artificial Chromosome
BFA: Brefeldin A
CBZ: carbamazepine
CDDO-Me: bardoxolone methyl (methyl-2-cyano 3,12-dioxooleano-1,9-dien-28-oate)
CLZ: clozapine
DCF: diclofenac
DDR: DNA damage response
DEM: di-ethyl maleate
DEM: Diethylmaleate
DILI: Drug-Induced Liver Injury
ER-stress Endoplasmic Reticulum stress
IAA: Iodoacetamide
INH: isoniazid
H₂O₂: hydrogen peroxide
HCI: High Content Imaging
HTS: High Throughput Screening
HTI: High Throughput Imaging
HTM: High Throughput Microscopy
KTZ: ketoconazole
MEN: menadione
MTX: methotrexate
NFZ: nefazodone
NPX: naproxen
NTF: nitrofurantoin
OFX: ofloxacin
OSR: Oxidative stress response/ antioxidant pathways
PHH: primary human hepatocytes
PI: propidium iodide
ROS: reactive oxygen species
SN: simvastatin
siRNA: small interfering RNA
Tc: Tunicamycin
Tg: Thapsigargin
TGZ: troglitazone
UPR: Unfolded Protein Response